Advertisement

Research Article Free access | 10.1172/JCI116396

Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3.

P Fishman, E Falach-Vaknine, R Zigelman, R Bakimer, B Sredni, M Djaldetti, and Y Shoenfeld

Hematology Research Unit, Golda Medical Center, Hasharon Hospital, Petach Tiqva, Israel.

Find articles by Fishman, P. in: PubMed | Google Scholar

Hematology Research Unit, Golda Medical Center, Hasharon Hospital, Petach Tiqva, Israel.

Find articles by Falach-Vaknine, E. in: PubMed | Google Scholar

Hematology Research Unit, Golda Medical Center, Hasharon Hospital, Petach Tiqva, Israel.

Find articles by Zigelman, R. in: PubMed | Google Scholar

Hematology Research Unit, Golda Medical Center, Hasharon Hospital, Petach Tiqva, Israel.

Find articles by Bakimer, R. in: PubMed | Google Scholar

Hematology Research Unit, Golda Medical Center, Hasharon Hospital, Petach Tiqva, Israel.

Find articles by Sredni, B. in: PubMed | Google Scholar

Hematology Research Unit, Golda Medical Center, Hasharon Hospital, Petach Tiqva, Israel.

Find articles by Djaldetti, M. in: PubMed | Google Scholar

Hematology Research Unit, Golda Medical Center, Hasharon Hospital, Petach Tiqva, Israel.

Find articles by Shoenfeld, Y. in: PubMed | Google Scholar

Published April 1, 1993 - More info

Published in Volume 91, Issue 4 on April 1, 1993
J Clin Invest. 1993;91(4):1834–1837. https://doi.org/10.1172/JCI116396.
© 1993 The American Society for Clinical Investigation
Published April 1, 1993 - Version history
View PDF
Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (April 1, 1993): No description
Advertisement
Advertisement